Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase

MMV390048, a member of a new class of inhibitors of the Plasmodium phosphatidylinositol 4-kinase, shows potential for both treatment and prophylaxis. A new antimalarial in the armamentarium Paquet et al. screened a small-molecule library against the human malaria parasite, Plasmodium falciparum, and identified the 2-aminopyridine chemical class with potent activity. The optimized compound from this class, MMV390048, was active against multiple parasite life cycle stages, in both the mammalian host and the mosquito vector, and also killed drug-resistant parasites. MMV390048 killed the malaria parasite by blocking the parasite’s phosphatidylinositol 4-kinase (PI4K) and was able to protect monkeys from malaria infection. MMV390048 has potential as a new antimalarial drug that may contribute to global malaria eradication efforts. As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-to-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model. Both genomic and chemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

[1]  J. McCarthy,et al.  Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development , 2016, Antimicrobial Agents and Chemotherapy.

[2]  R. Sauerwein,et al.  PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites , 2016, Antimicrobial Agents and Chemotherapy.

[3]  B. Kuster,et al.  Evaluation of Kinase Activity Profiling Using Chemical Proteomics. , 2015, ACS chemical biology.

[4]  Farah El Mazouni,et al.  A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria , 2015, Science Translational Medicine.

[5]  D. Mancama,et al.  Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination , 2015, Malaria Journal.

[6]  T. Bousema,et al.  A combination of new screening assays for prioritization of transmission-blocking antimalarials reveals distinct dynamics of marketed and experimental drugs. , 2015, The Journal of antimicrobial chemotherapy.

[7]  O. Vandal,et al.  Killing the hypnozoite – drug discovery approaches to prevent relapse in Plasmodium vivax , 2015, Pathogens and global health.

[8]  David W. Gray,et al.  A novel multiple-stage antimalarial agent that inhibits protein synthesis , 2015, Nature.

[9]  Scott Emrich,et al.  A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria , 2015, Nature.

[10]  M. Laufer,et al.  Antimalarial drug resistance in Africa: key lessons for the future , 2015, Annals of the New York Academy of Sciences.

[11]  P. Gething,et al.  Lead Clinical and Preclinical Antimalarial Drugs Can Significantly Reduce Sporozoite Transmission to Vertebrate Populations , 2014, Antimicrobial Agents and Chemotherapy.

[12]  Roger Le Grand,et al.  Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures , 2014, Nature Medicine.

[13]  K. Kuhen,et al.  KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage Parasites In Vitro , 2013, Antimicrobial Agents and Chemotherapy.

[14]  Robert W. Sauerwein,et al.  Targeting Plasmodium PI(4)K to eliminate malaria , 2013, Nature.

[15]  K. Chibale,et al.  Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum , 2013, Malaria Journal.

[16]  David M. Shackleford,et al.  In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models , 2013, Drug design, development and therapy.

[17]  K. Chibale,et al.  Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity. , 2013, Journal of medicinal chemistry.

[18]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[19]  D. V. van Schalkwyk,et al.  Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers , 2013, Malaria Journal.

[20]  M. Mota,et al.  Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins , 2013, Proceedings of the National Academy of Sciences.

[21]  B. Kuster,et al.  Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. , 2013, Journal of proteome research.

[22]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[23]  P. Gething,et al.  Transmission-blocking interventions eliminate malaria from laboratory populations , 2013, Nature Communications.

[24]  Geoffrey L. Johnston,et al.  Mitotic Evolution of Plasmodium falciparum Shows a Stable Core Genome but Recombination in Antigen Families , 2013, PLoS genetics.

[25]  K. Chibale,et al.  Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines. , 2012, Journal of medicinal chemistry.

[26]  A. Magill,et al.  Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. , 2012, The American journal of tropical medicine and hygiene.

[27]  G. Drewes,et al.  A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. , 2012, Nature chemical biology.

[28]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[29]  David M. Shackleford,et al.  3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. , 2012, Journal of medicinal chemistry.

[30]  Jeremy N. Burrows,et al.  P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action , 2012, PloS one.

[31]  Mark D. Johnson,et al.  Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion , 2011, Proceedings of the National Academy of Sciences.

[32]  Manor Askenazi,et al.  Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. , 2011, Analytical chemistry.

[33]  S. Hoffman,et al.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.

[34]  D. Kyle,et al.  Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) , 2011, Malaria Journal.

[35]  M. Mann,et al.  Large-scale phosphosite quantification in tissues by a spike-in SILAC method , 2011, Nature Methods.

[36]  I. Hastings,et al.  Development, Evaluation, and Application of an In Silico Model for Antimalarial Drug Treatment and Failure , 2011, Antimicrobial Agents and Chemotherapy.

[37]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[38]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[39]  Christian Scheurer,et al.  Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria , 2011, Proceedings of the National Academy of Sciences.

[40]  James R. Brown,et al.  Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery , 2011, BMC Evolutionary Biology.

[41]  Frank Fischer,et al.  Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays , 2010, Journal of the American Society for Mass Spectrometry.

[42]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[43]  David A. Fidock,et al.  Drug discovery: Priming the antimalarial pipeline , 2010, Nature.

[44]  L. Shultz,et al.  Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.

[45]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[46]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[47]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[48]  J. Chollet,et al.  In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. , 2007, Experimental parasitology.

[49]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[50]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[51]  A. Magill,et al.  Primaquine for prophylaxis of malaria: has the CYP sailed? , 2014, Journal of travel medicine.